AGIOAgios Pharmaceuticals

Median target
$41
calls from the last 12 months
Implied return
+22.0%
median target vs. price
Coverage
10 analysts · 12 calls
updated in the last 12 months
Consensus
7/3/0+7 net
Buy / Hold / Sell

Which analysts are behind AGIO's consensus?

See every current rating, price target and the analysts' track records for Agios Pharmaceuticals — plus the full analyst rankings, firm analytics and screener.

The consensus above reflects 10 analysts with calls on AGIO updated in the last 12 months. Implied return is the move implied if the consensus target were hit. These are forward-looking predictions, not realized returns. Per-analyst ratings and track records are a Premium feature.

AGIO elsewhere on AnalystEdge

The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.

Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)

DateSourceWhoActionDetailAmount
2026-08-04InsidersGheuens SarahChief Medical OfficerInsider sale30.0K sh @ $30.48 · planned trade$914K
2026-03-03CongressGilbert CisnerosCA-CA39Purchasesince trade +16.1%, vs market +3.9%$1K–$15K
2025-12-11CongressGilbert CisnerosCA-CA39Purchasesince trade +20.4%, vs market +9.3%$1K–$15K
2021-06-10ExecutiveLander, Eric SDirectorSaleAGIOS PHARMACEUTICALS INC$15,001 - $50,000
2015-05-27CongressThomas MacArthurNJ-NJ03Salesince trade -73.2%, vs market +403.7%$1K–$15K
2015-03-18CongressThomas MacArthurNJ-NJ03Purchasesince trade -68.8%, vs market -405.8%$1K–$15K

More: congressional trades on AGIO · insider activity · executive branch · trending